**OBJECTIVE**

To evaluate physician knowledge concerning aflibercept and to establish the afibercept educational needs.

**METHODS**

**Design**
- Cross-sectional survey of physicians involved in aflibercept therapy.
- Survey was conducted online after a sufficient amount of time for physicians to have received the educational materials and to have had on-hand experience with the product.

**Study Population**
- Physicians were recruited from six unique hospitals in Canada.

**Data Collection**
- The completed questionnaire was sent to all physicians.

**Analysis**
- Data were analyzed from March 10th through April 30th.

**RESULTS**

Knowledge of Key Safety Information
- The greatest physician knowledge was observed for correct use in women of childbearing potential and for recommendations that are not part of standard medical practice.

Knowledge of Physician Reactions to Questions on Dosing Recommendations for DME (N = 95)
- Nearly all physicians (93 of 95 [98%]) reported that they received the product monograph. Of those, 76% reviewed it.
- Nearly half of physicians (44 of 95 [46%]) reported that they received the intravitreal injection procedure card. Of those, 77% reviewed it.
- Most physicians (79 of 95 [83%]) reported that they received the vial preparation instruction card. Of those, 65% reviewed it.
- Physicians reported prescribing and/or administering aflibercept for wet age-related macular degeneration (wAMD) (94%), visual impairment due to age-related macular degeneration secondary to central retinal vein occlusion (CRVO) (87%), and macular oedema secondary to central retinal vein occlusion (CRVO) (81%).

**CONCLUSIONS**

- There is a need for focused educational programs to improve the understanding of aflibercept in the Canadian market.
- Physicians should be educated on the correct time frame for which women of childbearing potential must use effective contraception.

**CONFLICTS OF INTEREST**

None declared.

**REFERENCES**


2. **Contact Information**
   - Laurie Zografos, MD
   - Elizabeth Andrews
   - Dan Wolin, MD
   - Barbara Calingaert, MD
   - Elizabeth Davenport
   - Phone: +1.919.485.2782
   - E-mail: zdravko.vassilev@bayer.com

---

**DISCUSSION**

- In general, knowledge was high on questions about injection procedures (95% on individual items). However, fewer physicians (24%) correctly reported that, before marking the scleral injection site, the eye should be covered with a sterile drape.

**CONCLUSIONS**

- Physicians answered the questions of a screening question to confirm that they had received the educational materials and to have had on-hand experience with the product.

**CONTACT INFORMATION**

Laurie Zografos, MD
Elizabeth Andrews
Dan Wolin, MD
Barbara Calingaert, MD
Elizabeth Davenport
Phone: +1.919.485.2782
E-mail: zdravko.vassilev@bayer.com

---

**REFERENCES**


2. **Contact Information**
   - Laurie Zografos, MD
   - Elizabeth Andrews
   - Dan Wolin, MD
   - Barbara Calingaert, MD
   - Elizabeth Davenport
   - Phone: +1.919.485.2782
   - E-mail: zdravko.vassilev@bayer.com